Lonza 4D or equal nucleofection system

The Food and Drug Administration Office of Acquisition and Grant Services seeks quotation for two Lonza 4D nucleofection system units (one 4D-Nucleofector Core Unit and one 4D-Nucleofector X Unit, or equal), with quotations due August 3, 2026 at 11:00 AM Central Time.

Place of performance is Silver Spring, Maryland. The procurement is full and open to all sized businesses; NAICS code 334516 carries a 1,000-employee small business size standard.

The equipment must support transfection research on various cell lines including HEK293, CHO, and Huh7, with specific emphasis on difficult-to-transfect primary cells such as dendritic cells. Minimum requirements include post-transfection cell viability up to 90%, processing capacity of 2×10⁴ to 1×10⁷ cells per reaction, conductive polymer electrodes, and manufacturer-validated protocols for primary human dendritic cells. The contractor must deliver newly manufactured units (not refurbished) with factory-certified installation, on-site operator training for 3–5 users, one year of warranty including technical support, and complete documentation. Delivery, installation, and training must be completed within 120 days of award.

The contract is firm fixed-price. Pricing must be inclusive of shipping, on-site installation, user training, and applicable tariff charges. Quoters who are not manufacturers must provide original equipment manufacturer authorization letters. Quotations must include detailed technical specifications, descriptive materials, and scientific literature demonstrating compliance with all minimum requirements. Quoters must hold prices firm through September 30, 2026. Payment terms are Net 30 days after government acceptance, with invoices submitted electronically through the Department of Treasury Invoice Processing Platform. Submit quotations by email only to Suzanne Martella (suzanne.martella@fda.hhs.gov), referencing solicitation 75F40126Q134795, and include the Unique Entity ID number.